Death Points to Risks in Research
One Woman's Experience in Gene Therapy Trial
Highlights Weaknesses in the Patient Safety Net
By Rick Weiss
Washington Post Staff Writer
Monday, August 6, 2007; A01
Robb Mohr sat by his wife's hospital bed two weeks ago, trying to take it all in. His wife, Jolee Mohr, was
breathing with the help of a ventilator in a Chicago intensive care unit -- her body bloated from internal
bleeding, her liver failing -- and no one could figure out what was wrong with her.
Robb Mohr had his suspicions. Jolee, 36, had been feeling fine just a few weeks earlier, save for
occasional stiffness from her arthritis. Her decline had begun the day after her right knee was injected
with an experimental drug made of genetically engineered viruses. Doctors at the hospital shared his
concern.
Jolee Mohr died from massive bleeding and organ failure July 24, leaving behind a 5-year-old daughter
and a host of questions about why she was recruited into a gene therapy experiment whose chief goal
was to test the safety of a novel arthritis treatment that had virtually no chance of helping her.
No one knows yet whether the treatment was to blame. Of the dozens of other volunteers who got the
injections, only Mohr suffered anything more than short-lived side effects, said officials at Targeted
Genetics Corp., the Seattle company that makes the product. The Food and Drug Administration and the
company are investigating.
But a close look at the events leading to Mohr's death reveals failures in the safety net that is supposed
to protect people from the risks of medical experimentation -- and in particular, the risks of gene
therapy, which for 17 years has struggled in vain to live up to its optimistic name.
Breaches of clinical research standards and a federal oversight system that allowed key decisions to be
made behind closed doors may have helped draw Mohr into an experiment that was not, her husband
says, what she thought it was.
"It was presented to her like this is going to make her knee better," said Robb Mohr, an agronomist who
lived with his wife of nine years in a modest vinyl-sided ranch home near Springfield, Ill. "It was
supposed to be just a simple thing."
Company officials vigorously defend the study, saying they were upfront about risks, adhered to all
regulations and were terribly saddened by the loss. "We're human," said H. Stewart Parker, Targeted
Genetics' chief executive. "This is not just a patient. This is a person, and this is a horrible tragedy."
A two-sentence paragraph halfway through a 15-page consent document that Jolee Mohr signed warns
of the possibility of "unknown side effects," including, "in rare circumstances, death."
Further in, after long descriptions of how the product may help, a single sentence states: "We do not
expect you to receive any direct medical benefits from participation in this study."
Mohr was in an early-phase study, the prime goal of which was to see whether the treatment was safe,
not to provide a therapeutic benefit. If the drug passed muster, other studies would determine whether it
was an effective treatment.
Her rheumatologist, Robert Trapp, whose Springfield clinic got payments from Targeted Genetics for
each subject he recruited, also defended the study. "The theory behind it seemed good, and the science
seemed good," he said. "There's nothing I knew of that could have predicted this."
Arthritis is a disease in which the immune system attacks the joints, causing painful inflammation and
degradation. Even when treated with powerful medicines, up to 40 percent of patients have ongoing pain
in at least a few joints.
That medical reality is an economic opportunity worth as much as $3 billion a year, Parker has said. The
company hopes to tap that market with tgAAC94, a virus engineered to have an extra gene. Injected into
a joint, the virus infects cells and continuously produces proteins that sop up inflammatory molecules,
according to the company.
Like other gene therapies -- hundreds of which have been tested since 1990 and all of which are still
experimental -- the approach has the potential advantage of having the body crank out its own medicine
for months or years after treatment, right where it is needed.
That sounded good to Mohr when Trapp, one of 20 U.S. doctors testing tgAAC94, invited her to join the
study on Feb. 12.
There would be two injections, months apart, he explained. The first might be real, or it might be a
placebo, but the second would definitely be the test product. She signed up immediately, and Trapp
drew several tubes of blood to get the study going.
Two fundamental rules of clinical research were violated that day, experts said. First, consent forms are
to be taken home and considered, not signed on first sight. Second, when a patient's own doctor is a
principal investigator in a study, someone else is supposed to make the proposal.
"Because of the relationship . . . you have to worry that they won't listen carefully enough to the risks,"
said Hank Greely, director of the Center for Law and the Biosciences at Stanford University. Patients, he
said, may think, " 'After all, if my doctor is doing this, it must be good for me.' That can be difficult to
overcome with words in a consent form."
Trapp said he thoroughly explained the risks to Mohr.
Jonathan Moreno, an expert in the ethics of medical experiments at the University of Pennsylvania, said
the consent form used by Targeted Genetics to outline the drug's potential dangers was thick with
technical descriptions and thin on explaining "what's really going to happen."
"Even a smart person would have a very hard time figuring out what they're talking about," said
Moreno, who examined the form at the request of The Washington Post.
The form was approved by one of the growing number of for-hire review boards that contract with
biotechnology companies to ensure studies meet patient-protection standards. Targeted Genetics noted
that the review firm it used is accredited and accepted by the FDA. But the use of private boards, as
opposed to those run by universities or government agencies, has raised alarms among some medical
ethicists since a for-profit review board risks losing repeat business if it is too tough on its clients.
Mohr's first shot, administered on Feb. 26, had no noticeable effect, and she wondered whether she got
the placebo. But she was excited that the next one would be the real thing, Robb Mohr said.
That happened on July 2, a Monday. She was tired and out of sorts after a weekend of boating with her
husband and daughter, but she had gone to her data-entry job at the secretary of state's office in
Springfield and later to Trapp's office.
He recorded her temperature at 99.6, then gave her the shot.
"The next day she woke up and didn't feel good at all. By afternoon she started vomiting," Robb Mohr
recalled. "By evening her temperature had shot up to 101."
She spent July Fourth feverish and vomiting. Her family physician told her it was probably just a virus.
When her symptoms worsened and her temperature hit 104.1 on Saturday, she went to the emergency
room. Tests indicated a possible infection and signs of liver damage, but she was sent home for more
care from her family doctor, according to Robb Mohr and medical records.
Aware of the experiment, Mohr's family doctor called Trapp, who reassured him that the virus was safe
- something Trapp said he had learned at a training session sponsored by Targeted Genetics. But Mohr
only got worse, and on Thursday she was admitted to the hospital.
Things went downhill fast, with Mohr's body showing signs of being ravaged by an infection. But tests
for standard bacteria and viruses came up negative. With breathing problems and the possibility she
might need a liver transplant, she was transferred to the University of Chicago hospital.
Suspecting a possible link to the experimental drug, the doctors in Chicago contacted the FDA.
Federal regulations require a company to report any serious complications that are even "possibly"
related to an experimental treatment "as soon as possible" and no later than seven days after learning of
it. But Targeted Genetics and Trapp had at first classified the problems as not serious, and later
classified them as serious but unrelated to the treatment. So no FDA report was made, and the study
went on, with other volunteers unaware of the problems.
That reflects a widespread problem in clinical trials, said Adil Shamoo, a professor at the University of
Maryland School of Medicine and editor in chief of the journal Accountability in Research.
"There are no uniform standards for 'adverse events' reporting," Shamoo said. "And there is no
motivation to report them. . . . No one wants to show their dirty linen."
Dirty linen can drag down a company's bottom line, and Targeted Genetics, like all companies, puts a lot
of work into keeping that line afloat. An interim report on tgAAC94, for example, spoke in June of
"very encouraging results" and evidence of "clinical benefit," although, by one measure the company
considered key, patients who got high, medium or low doses of the drug did the same as those who got
placebos.
"The company was talking about lucrative markets and a promising product much too soon," said Marcy
Darnovsky, associate executive director of the Center for Genetics and Society, an Oakland, Calif.-based
public interest group that focuses on genetic technologies.
Company officials said the drug does show promise by some measures. "We don't know what the best
indication of efficacy is yet," said Barrie Carter, the company's chief scientific officer.
Finally, on July 20, a day after Mohr's emergency transport to Chicago and four days before she died,
the company sent a "serious adverse event" report to the FDA and suspended the study, conceding that
her life-threatening symptoms were "possibly" due to the treatment.
Three weeks after Mohr got the injection that she had hoped would cure her, she was unconscious and
beyond hope of recovery. With family and friends gathered around, her life support was removed.
"Basically, I told my daughter that her mommy has died and gone to live with Jesus," Robb Mohr said.
"She prays every night that Jesus will make her better so she can come back home."
Tests on Jolee's Mohr's tissues may tell the story of what happened, but for now scientists say they are
scratching their heads.
One reassuring aspect of tgAAC94's engineering is that genes required for replication have been
removed, so the viruses cannot make more of themselves. But animal studies conducted by the company
have shown that the product can escape from the joint space and travel about the body, perhaps catching
the attention of the immune system. In general, the immune system mounts much more robust --
sometimes dangerously robust -- responses after a second exposure. In fact, both shots Mohr got were
the real thing, the company said.
Further complicating matters, Mohr was on three conventional but potent arthritis drugs, each of which
can cause serious side effects.
Years ago, when Targeted Genetics first sought permission to test tgAAC94 in people, federal reviewers
approved a single dose in patients who were not taking other drugs but said they would think twice
about approving multiple shots or testing in people taking other arthritis medications. Some questioned
whether the risk of even a single shot was worth it for a non-life-threatening disease such as arthritis,
according to the minutes of meetings at the National Institutes of Health, which used to review, in
public, every proposed human gene therapy experiment.
After completing its initial study of single shots, Targeted Genetics sought permission to start giving
two -- and to patients taking other drugs. Whatever discussion led up to that approval is hidden from the
public because of a federal rule change in 2000 that placed most such follow-on studies under
confidential FDA review rather than a public NIH process.
In testimony before a congressional subcommittee in 2000, a chief executive representing the
Biotechnology Industry Organization spoke out for the rule change, to streamline oversight and
harmonize NIH and FDA regulations. Among other things, the change gave companies up to a year to
report serious adverse events as long as the doctor overseeing the study does not think the problem is
caused by the test product.
The chief executive was H. Stewart Parker of Targeted Genetics.
http://www.washingtonpost.com/wp-dyn...07080501636_pf.... 8/6/2007

What can anyone say after reading this but to thank you Paula for keeping
up the work you are doing to help those who are being so deceived by those they trust.

There really is no one to blame in this as they are all equally to blame for this really is a hatefull money hungry society we live in.

Some will jump on the family doctor and some the research company and some will attribute this to an act of god some will of course jump on the stem cells themselves. But whatever they come up with will be levered by the fact that all of society now is in the throes of self annilation and I see no out for us.

Hatfull deeds followed by attrition is the name of the game be it religion or politics or self proclaimed moral proclamations of innocence.

Again there is you to lend hope thank you

Thank you Thelma altho I don't like being the bearer of this kind of news. This article did clear up the question I had about a second shot of the virus being a factor - it sounds like she had the placebo with the first shot. So those who already have the virus hopefully are safe from that kind of immediate reaction. They aren't meeting until September; I hope they all go to the meeting fully informed so as not to waste time.

Must include a disclaimer that her death has not been proven to have been caused by the treatment.

paula